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Abstract
Purpose: Although [18F] FDG-positron emission tomography (PET) provides vital information in diagnosing lung malignancies,
the inherent uncertainties of standard uptake value (SUV) compromises its confidence. People have attempted to reduce this
uncertainty by comparing the normal tissues, such as liver and spleen. However, those common reference structures may be
inappropriate in some cases when pathological conditions exist. Hence, using alternative reference structures becomes valuable
in such practice.  The purpose of this study is to explore an alternative reference-correction method to reduce the inherent
variation of SUV in the tumor or irradiated region. Methods: 106 analyzable FDG-PET scans from 49 cases who received lung
SBRT for non-small cell lung cancer were retrospectively analyzed. The follow-up time ranges from 14.5 weeks to 113.2 weeks.
The maximal SUV (SUVmax) was measured within the lung lesion or its corresponding region in post-SBRT. SUVmax was then
corrected (or divided) by a reference SUV, or the mean SUV of the adjacent aorta, and results in the new SUVcmax. Results:
SUVcmax of the positive group are significant higher than that of locally controlled cases (5.82 ± 3.10 vs. 1.45 ± 0.55, p = 0.026),
while inconsequential differences were identified between the groups (p = 0.086). Respectively 85.2% and 96.3% of locally con-
trolled cases post SBRT showed decreased values in the latter PET using SUVmax and SUVcmax. PET taken 24 weeks or sooner
post-SBRT yielded higher uncertainties. Conclusion: Comparing with the conventional SUVmax, the alternative regional back-
ground-corrected SUV indicator, SUVcmax of PTV suggests a stronger correlation between low (<2.5 - 3.0) values and the local
tumor control post lung SBRT for NSCLC. However, FDG-PET images taken earlier than 24 weeks post-SBRT presents larger
variations in SUV of the irradiated region due to underlying radiation induced inflammatory changes, and is not recommended
for assessing local tumor control after lung SBRT.
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Introduction
Today, lung cancer is still the leading cause of cancer-related
death in men and women in the United States.1 In addition
to surgical resection and radiation therapy, lung stereotactic
radiation therapy (SBRT) has become a popular option for
early stage non-small cell lung carcinoma (NSCLC).2 With
improved image guidance and respiratory motion control,
lung SBRT has shown excellent local control in comparison
to surgery.3, 4, 5 Functional imaging, such as [18F] FDG-
positron emission tomography (PET) provides helpful meta-
bolic information in diagnosing, staging, and in predicting
the local control of lung malignancies post lung SBRT.6, 7
However, no standard uptake value (SUV) level has been
widely accepted for suggesting a local lung cancer recurrence
due to large inherent and post-irradiation added variations.
Efforts have been suggested in reducing the inherent varia-
tions of SUV with limited success.8, 9, 10 However, those
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common reference structures may be inappropriate in some
cases due to the preexisting pathologies, alternative reference
structures shall bring value to such practice. Furthermore,
approximately 10% to 20% of all lung cancer patients treated
with radiotherapy present evidence of radiation-induced
lung changes 11, 12 making the assessment of the tumor local
control of post lung SBRT more difficult.
The purpose of this study is to explore an alternative refer-
ence-correction method to reduce the inherent variation of
SUV in the tumor or irradiated region, and provide a modi-
fied SUV indicator for monitoring the tumor local control of
NSCLC treated with lung SBRT.
Methods and Materials
A total of 49 qualified or 50% of all lung cancer patients
treated with intensity modulated lung SBRT in this institute
from May 2009 to August 2010 were analyzed retrospective-
ly. From them, 106 PET image sets were obtained and in-
cluded in this investigation. The selected case must provide a
pathological report NSCLC, and an analyzable pretreatment
PET or at least one post-SBRT PET studies. The mean age of
the group was 82.3 ± 9.3 years old. The pre-SBRT PET images
and four post-SBRT PET from the only two locally relapsed
cases comprise the "Positive” group (n = 37). The "Controlled"
group consisted of the remaining 69 PET images from the 47
locally controlled cases following lung SBRT.
All the cases had 4D CT simulation and the treatment volume
or planning tumor volume (PTV) contains the entire internal
tumor volume (ITV) plus a 3-7 mm margins according to the
tumor motion. The setup alignment was guided by 3D
cone-beam CT and accomplished by joint the 4D patient
support system (Varian Medical Systems, Palo Alto, CA) and
Protura™ 6D robotic couch system (CVICO Medical Solu-
tions, Coralville, IA). The SBRT was executed by multiple 6
MV photon beams gated for full-range of respirations using a
Novalis TX CLINAC (Varian Medical, California) for a dose of
50 Gy in 5 consecutive fractions. In this collection, all
FDG-PET studies were conducted with a GE Discovery STE™
or a Philips TF™ scanner, in which those reported in
non-SUV format were excluded from database. The sampling
of background reference SUV (SUVref) was taken from the
adjacent aorta. The SUVmax of the PTV or irradiated volume
were measured, as shown in Figure 1.
To ensure the consistency of the process, all PET images and
pretreatment 4D simulation CT images were first transferred
to Brainlab (Feldkirchen, Germany) iPlan™ Image v4.1 and
fused to the average intensity projection 4DCT set. SUVref
was measured within three or four consecutive slices of the
aorta adjacent to the tumor, excluding visible hotter or cold-
er spots. This value can be expressed as:
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In this study lung tumor local control was analyzed inde-
pendently from mediastinal failure, distant metastases, and
overall survival.
Results
The mean PET follow-up time post-SBRT is 49.4 weeks (11.5
months), ranging from 14.5 weeks (3.4 months) to 113.2
weeks (26.4 months). The SUVref of the regional aorta over
the entire 106 PET images ranges from 1.06 ± 0.14 to 2.40 ±
0.23 with a mean of 1.76 ± 0.32.
The mean SUVmax (6.34 ± 5.20) of the Positive is indistin-
guishable from the mean SUVmax of the controlled (p >
0.05), as tabulated in Table 1. However, SUVcmax signified
this comparison with a larger difference between the two
groups means (5.82 ± 3.10 vs. 1.45 ± 0.55, p = 0.026).
TABLE 1: Comparison of PET between the positive and locally con-
trolled groups during 14 to 113 weeks post SBRT
SUVmax SUVcmax
Group Positives Controlled Positives Controlled
Mean value 6.34 2.55 5.82 1.45
SD 5.20 1.13 3.10 0.55
Minimum 0.58 1.31 0.34 0.75
Maximum 25.14 7.62 13.38 3.90
Observations 37 69 37 69
p-value(2x
controlled SD)
0.086 0.026
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FIG.1: Tumor SUVmax of pre- and post-SBRT PET scans.
FIG. 2: SUVmax comparison between the locally controlled cases
post lung SBRT (shown as blue diamonds) and the mean of positive
lung cancer cases (marked as red band), where moderate separation
can be seen especially with late PET studies.
FIG 3: SUVcmax comparison between the locally controlled cases
post lung SBRT (shown as blue diamonds) and the mean of positive
lung cancer cases (marked as red band), where clear separation can
be seen especially with late PET studies.
When comparing post-SBRT PET images up to 65 weeks
after irradiation, no significant differences can be concluded
between the Positive and Controlled in SUVmax (p > 0.05)
and SUVcmax (p > 0.05). However, when PET images earlier
than 24 weeks post-SBRT are excluded from the comparison,
the locally controlled group displays noticeably lower SUV
with either SUVmax (p = 0.013) or SUVcmax (p = 0.008). In
addition, the false positive rates are also reduced from 34.7%
to 26.5% when using cutoff value of 3.0 for SUVmax (as in
Table 2) and from 26.5% to 17.6% when using cutoff value
of 1.8 for SUVcmax (as in Table 3).
TABLE 2: Comparison of PET scans of recurrent lung cancer cases
and locally controlled cases post SBRT during selected periods pre-
sented in SUVmax.
SUVmax Positives Locally
controlled
PET
Post-SBRT (weeks) Pre/post 14-65 24-65
Mean value 6.34 2.82 2.47
SD 5.20 1.22 0.81
Minimum 0.58 1.33 1.33
Maximum 25.14 7.62 4.49
Observations 37 49 34
SUVmax > 3.0 70.3% 34.7% 26.5%
p-value(2x controlled SD) N/A 0.224 0.013
TABLE 3: Comparison of PET scans of positive group and locally
controlled cases post SBRT during selected periods presented in
SUVcmax.
SUVcmax Positives Locally
controlled
PET
Post-SBRT (weeks) Pre/post 14-65 24-65
Mean value 5.82 1.57 1.41
SD 3.10 0.60 0.44
Minimum 0.34 0.75 0.75
Maximum 13.38 3.90 2.41
Observations 37 49 34
SUVcmax > 1.8 70.3% 26.5% 17.6%
p-value (2x controlled SD) N/A 0.068 0.008
In the locally controlled group, 27 out of 69 cases had more
than one post-SBRT PET collected, in which 85.2% or 23
cases with SUVmax and 96.3% or 26 cases with SUVcmax
showed progressively lower values.
Discussion
FDG-PET is now a common tool used in lung cancer diagno-
sis, radiation treatment planning, and post irradiation moni-
toring. While providing visual differentiation, SUVmax of
the volume of interest has been frequently employed as the
crucial indicator in the diagnostic or treatment evaluating
process for NSCLC. Its thresholds vary around 2.5 13, 14, often
ranging from 2.0 15 to 5 or higher.16 One study reported that
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the outlined tumor volumes using a threshold of 3.0 ± 1.6
matched closely to the dimension measured pathologically in
nine NSCLC cases.17 Alternatively, the percent constant
threshold between 20% and 42% of maximum concurs with
results from pathology. An adaptive threshold method sug-
gests an improvement in using SUVmax when the ratio of
tumor to background levels is used 18, even though its adapt-
ability varies depending on the background variable defined
by the user.19, 20 At present there is still no clear consensus as
to the appropriate threshold for tumor detection.
The inherent variations of SUV have been broadly acknowl-
edged. The common variables include physiological (meta-
bolic activity changes, blood glucose level), pathological
(local inflammatory changes), and physical (relative activity
per body volume at imaging, acquisition parameters, effi-
ciency of the PET system) changes.21 In addition, tumor mo-
tion reduces SUVmax and SUV-defined volume in conven-
tional PET.22, 23 Hence, simple quantitative techniques for
SUV analyses to separate benign from malignant tissues are
still highly debatable. When a threshold of SUVmax for de-
fining malignancy is derived from a retrospective study, it
may introduce a risk of misguidance for patient data groups
24 using PET from different facilities. Regardless of such lim-
itations, the impartiality of quantitative classification by the
SUV still makes it a valuable and subjective adjunct to visual
analyses. To overcome these uncertainties, some investiga-
tors have proposed the subtraction of normal tissue uptakes
from tumor SUV.25 However, those studies fail to show re-
producibility, mainly due to inconsistent tissue sampling and
SUV variations in the reference organs.26 In our study, the
aorta nearby the lesion was chosen as the reference site,
which inherently provides more reliable and reproducible
reference values as long as hot or cold spots are avoided. In
contrast to other organs, the aorta generally shows more
constant SUV values with less motion or pathological effect.
Such SUVref values can always be measured at the proximity
to the tumor in the similar condition of data acquisition. In
fact, each scan introduces a group of variables causing un-
certainties in SUV values. Therefore, there was a pressing
need for a method to allow corrections to be made within
each PET study using a reproducible correction factor. With
this optimized correction method, a new SUV, represented
by the ratio of SUV's between the tumor site and reference,
reveals the reality of canceling most potential variables be-
tween scans, such as those in dynamic evaluation of lung
lesions. During aortic reference sampling, visible hot or cold
spots of the aorta due to motion artifact or pathological
changes on the arterial wall 27 were carefully avoided. Often
the elevated value is associated with atherosclerosis, dissec-
tion vasculitis (ie Takayasu’s) and thoracic stent graft place-
ment related to the thoracic aortic wall inflammatory
changes.28 Although SUVref is the measurement of the FDG
concentration in the blood flow, it is relatively equivalent in
principle to the reference using SUV of other FDG accumu-
lated regions, such as liver and spleen if the variation is not
of concern. Comparatively, SUVcmax in this study demon-
strated a stronger correlation with locally controlled NSCLC
cases post lung SBRT than the conventional SUVmax did (p =
0.026 vs. 0.086). This correlation between low SUVcmax (<
3.0) value and the prediction of local control post-treatment
is further suggested in Figure 3, while less separation from
the recurrent cases is shown when using SUVmax (Figure 2).
Table 1 displays large deviations in SUVmax within the Posi-
tive mainly caused by a few extremely low SUVmax cases in
the pre-SBRT PET scans. Clinically lung lesions less than 0.6
- 1 cm in diameter often show exceptionally low SUV in
PET, and are difficult to quantify with the limited resolution
of a PET scanner. Furthermore, lesions in the lower lobes of
the lungs exhibit larger motions which lead to a reduction of
SUV. Authors include the low SUV images in the Positive to
make the statistical results more conservative.
Although IMRT based lung SBRT may show some reduction
of normal tissue toxicities 29, in post lung SBRT the acute
inflammatory changes at the lung are unavoidable.30 These
acute inflammatory changes are often difficult to distinguish
from the uncontrolled local malignancy, and interfere with
clinical judgment. Since FDG itself is a nonspecific tracer, it
also detects local inflammatory changes such as a region of
enhanced FDG uptake. Many cohort studies for lung SBRT
follow-ups also address such concerns.31 Since the irradiation
induced inflammation tends to subside within 3-6 months 32,
most investigators prefer the initial post-irradiation scan to
be no sooner than 6 months after radiation is complete.
Contrarily, at least one author believes that a single PET scan
at 12 weeks could be used to tailor further follow-up ac-
cording to the risk of failure.33 To promote this early predic-
tion, Koike et al reported a dual-time FDG-PET imaging
method with potential usefulness for predicting early relapse
of malignant tumors as early as 3 months after lung SBRT.34
Our results however showed that PET scans earlier than
24-weeks post lung SBRT introduced huge uncertainties in
predicting local control, as implied in Table 2 and 3. Only
when the early PET studies were excluded, both SUVmax
and SUVcmax of post-treatment fell in false positive rates (p
< 0.015) and showed less standard deviation. Dunlap et al
suggested that three consecutive increases in volume of FDG
PET and an increase in volume at 12 months after lung SBRT
in mass-like consolidation were highly specific for tumor
recurrence.35 In our 27 out of 47 locally controlled cases who
had two available post-therapy PET images, 23 (85%) and 26
(96%) showed decrease in SUVmax and SUVcmax with their
subsequent PET and provided further support for the tumor
control. In comparing figure 2 to 3, post-treatment SUVcmax
appeared more convincing in differentiating the controlled
group from the Positive by a value of 2.5 - 3.0 than SUVmax
did. The author believes that the SUVcmax is promising in
predicting local control of post lung SBRT although studies
with a larger case number, especially with more recurrent
cases may be warranted.
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Conclusion
Comparing with the conventional SUVmax, the alternative
regional background-corrected SUV indicator, SUVcmax of
PTV suggests a stronger correlation between low (<2.5 - 3.0)
values and the local tumor control post lung SBRT for
NSCLC. However, FDG-PET images taken earlier than 24
weeks post-SBRT presents larger variations in SUV of the
irradiated region due to underlying radiation induced in-
flammatory changes, and is not recommended for assessing
local tumor control after lung SBRT.
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